Drug development models for ultra-rare disorders

Susan J. Hayflick, Chris Andon, Antoinette D. I. van Asselt, Harm Jan Hektor, Ody Sibon
Nature Reviews Neurology · Springer Nature · 2026-11-16 · DOI: 10.1038/s41582-026-01295-8

Abstract

Nature Reviews Neurology, Published online: 16 November 2026; doi:10.1038/s41582-026-01295-8 The traditional for-profit model of drug development is not sustainable for rare and ultra-rare neurological conditions, so alternative models are needed. Here, we consider some of the programmes and initiatives that are providing viable pathways.

Read at publisher →

Similar articles